Tricare extends OTC demo
This article was originally published in The Tan Sheet
The Department of Defense's Tricare health care program extends a demonstration project that allows substituting OTC products for some Rx allergy and heartburn drugs. According to a Nov. 5 release, Tricare beneficiaries can ask health care providers for prescriptions for OTC medications instead of Rx brand and generic cetirizine and loratadine allergy medications and omeprazole proton pump inhibitors. The Falls Church, Va.-based benefits provider said the program was scheduled to end Nov. 4, but will continue indefinitely. Tricare now requires $3 copays to cover changes in the overall benefits program. Like Tricare, other pharmacy benefit programs are conducting pilots or have started covering some OTC drugs (1"The Tan Sheet" May 5, 2008). The American Lung Association recently asked Congress to mandate coverage of some smoking-cessation methods, including OTCs (2"The Tan Sheet" Nov. 16, 2009)
You may also be interested in...
The American Lung Association calls on lawmakers to use health care reform legislation to mandate coverage of government-recommended methods, including OTCs, for quitting smoking under Medicaid, state and private insurance plans
Data not only show some consumers are choosing OTC Zyrtec over other nonprescription allergy drugs they previously used, but also that managed-care plans have growing influence on OTC choices, according to Nielsen market research firm executive Matt Dumas
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.